Axon Enterprise, Inc. (NASDAQ:AXON) CEO Patrick W. Smith Sells 71,499 Shares

Axon Enterprise, Inc. (NASDAQ:AXON – Get Rating) CEO Patrick W. Smith sold 71,499 shares of the firm’s stock in a transaction dated Tuesday, January 17th. The stock was sold at an average price of $185.77, for a total transaction of $13,282,369.23. Following the completion of the transaction, the chief executive officer now owns 2,254,734 shares of the company’s stock, valued at $418,861,935.18. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Axon Enterprise Price Performance

Shares of AXON opened at $185.02 on Friday. The firm has a market cap of $13.17 billion, a PE ratio of 127.60 and a beta of 0.79. The firm’s 50 day moving average price is $177.44 and its 200 day moving average price is $145.13. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.39 and a current ratio of 2.79. Axon Enterprise, Inc. has a twelve month low of $82.49 and a twelve month high of $193.85.

Axon Enterprise (NASDAQ:AXON – Get Rating) last issued its quarterly earnings data on Tuesday, November 8th. The biotechnology company reported $0.30 earnings per share for the quarter, beating the consensus estimate of $0.06 by $0.24. The firm had revenue of $311.75 million for the quarter, compared to analyst estimates of $276.99 million. Axon Enterprise had a net margin of 9.75% and a return on equity of 9.88%. As a group, research analysts expect that Axon Enterprise, Inc. will post 0.54 EPS for the current fiscal year.

Analyst Ratings Changes

Several research analysts have commented on the stock. Morgan Stanley raised their target price on shares of Axon Enterprise from $130.00 to $155.00 and gave the stock an “equal weight” rating in a report on Tuesday, December 13th. Northland Securities raised their price target on shares of Axon Enterprise from $140.00 to $160.00 in a report on Wednesday, November 9th. StockNews.com assumed coverage on shares of Axon Enterprise in a report on Wednesday, October 12th. They set a “hold” rating for the company. Robert W. Baird raised their price target on shares of Axon Enterprise from $170.00 to $200.00 in a report on Thursday, December 15th. Finally, Credit Suisse Group raised their price target on shares of Axon Enterprise from $152.00 to $200.00 and gave the stock an “outperform” rating in a report on Tuesday, January 10th. Two investment analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $181.13.

Hedge Funds Weigh In On Axon Enterprise

Several hedge funds and other institutional investors have recently added to or reduced their stakes in AXON. Capital International Investors raised its position in shares of Axon Enterprise by 605.2% in the first quarter. Capital International Investors now owns 2,660,634 shares of the biotechnology company’s stock valued at $366,449,000 after purchasing an additional 2,283,343 shares during the period. William Blair Investment Management LLC boosted its stake in shares of Axon Enterprise by 22.2% in the 2nd quarter. William Blair Investment Management LLC now owns 2,130,903 shares of the biotechnology company’s stock valued at $198,536,000 after purchasing an additional 386,861 shares in the last quarter. State Street Corp raised its holdings in shares of Axon Enterprise by 13.3% in the first quarter. State Street Corp now owns 2,220,692 shares of the biotechnology company’s stock valued at $305,856,000 after buying an additional 261,508 shares during the last quarter. Allianz Asset Management GmbH raised its holdings in shares of Axon Enterprise by 125.9% in the second quarter. Allianz Asset Management GmbH now owns 243,466 shares of the biotechnology company’s stock valued at $22,683,000 after buying an additional 135,696 shares during the last quarter. Finally, Sei Investments Co. raised its holdings in Axon Enterprise by 586.5% during the 2nd quarter. Sei Investments Co. now owns 147,653 shares of the biotechnology company’s stock worth $13,757,000 after purchasing an additional 126,144 shares during the last quarter. Institutional investors own 75.62% of the company’s stock.

About Axon Enterprise

(Get Rating)

Axon Enterprise, Inc engages in the development, manufacture, and sale of conducted electrical weapons for personal defense. It operates through the TASER segment and Software and Sensors segment. The TASER segment sells conducted electrical weapons, accessories, and other related products and services.